Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?

Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block?. Ducreux, M.; Pignon, J. P.. Eur J Cancer. 2016; 178-179: p.178-179. doi:10.1016/j.ejca.2016.10.001 10.1016/j.ejca.2016.10.001. Epub 2016 Nov 10.

Article